Pathology & Laboratory Medicine

Publications

Filter By Faculty

Filter by Principal Investigator

2019

Reina-Campos M, Linares JF, Duran A, Cordes T, L'Hermitte A, Badur MG, et al. Increased Serine and One-Carbon Pathway Metabolism by PKCλ/ι Deficiency Promotes Neuroendocrine Prostate Cancer. Cancer Cell. 2019;35(3):385-400.e9.

Cross T, Ransegnola B, Shin J-, Weaver A, Fauntleroy K, VanNieuwenhze MS, et al. Spheroplast-Mediated Carbapenem Tolerance in Gram-Negative Pathogens. Antimicrob Agents Chemother. 2019;63(9).

Hirsch Y, Zeevi DA, Lam BL, Scher SY, Bringer R, Cherki B, et al. A founder deletion in the TRPM1 gene associated with congenital stationary night blindness and myopia is highly prevalent in Ashkenazi Jews. Hum Genome Var. 2019;6:45.

Jin C, Huang Y, Nasim M, Yang Y, Lee L. Gastrointestinal Stromal Tumors Risk Stratification Utilizing Phospho-Histone H3 Evaluated by Manual Counting and Computer-Assisted Image Analysis. Int J Surg Pathol. 2019;27(7):706-712.

Baum JE, Soong L, Scognamiglio T, Margolskee EM, Hoda RS, Rao R. Cytological diagnosis of papillary thyroid carcinoma with tall cells on ThinPrep liquid-based cytology. Diagn Cytopathol. 2019;47(6):541-546.

Ahmed A, Crowson N, Magro CM. A comprehensive assessment of cutaneous Rosai-Dorfman disease. Ann Diagn Pathol. 2019;40:166-173.

Sun L, Thorson T, Zhu R, Huo J, Tong J, Rodgers WH, et al. A case report of parotid mammary analogue secretory carcinoma and reviews. Int J Surg Case Rep. 2019;55:88-91.

Beltran H, Oromendia C, Danila DC, Montgomery B, Hoimes C, Szmulewitz RZ, et al. A Phase II Trial of the Aurora Kinase A Inhibitor Alisertib for Patients with Castration-resistant and Neuroendocrine Prostate Cancer: Efficacy and Biomarkers. Clin Cancer Res. 2019;25(1):43-51.

Puca L, Gavyert K, Sailer V, Conteduca V, Dardenne E, Sigouros M, et al. Delta-like protein 3 expression and therapeutic targeting in neuroendocrine prostate cancer. Sci Transl Med. 2019;11(484).

Martin P, Ruan J, Furman R, Rutherford S, Allan J, Chen Z, et al. A phase I trial of palbociclib plus bortezomib in previously treated mantle cell lymphoma. Leuk Lymphoma. 2019;60(12):2917-2921.